Category «Uncategorized»

Vicadrostat

Vicadrostat CAS 1868065-21-7 MF C15H12ClN3O3 MW 317.73 2-chloro-4-[(6R)-6-(hydroxymethyl)-6-methyl-4-oxo-6,7-dihydropyrano[3,4-d]imidazol-3(4H)-yl]benzonitrilealdosterone synthase inhibitor, BI 690517, AF4VW4GA3H Vicadrostat is an aldosterone synthase inhibitor (IC50=48 nM). Vicadrostat can be used for research in kidney diseases and cardiovascular diseases Vicadrostat (BI 690517) is an investigational drug by Boehringer Ingelheim that selectively blocks aldosterone synthase, reducing excess aldosterone linked to kidney, heart, and metabolic diseases like chronic …

Varegacestat

Varegacestat CAS 1584647-27-7 MF C26H25F7N4O3 MW574.5 (2R,3S)-N1-[(3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)butanediamide (2R,3S)-N1-((3S)-5-(3-FLUOROPHENYL)-2,3-DIHYDRO-9-METHYL-2-OXO-1H-1,4-BENZODIAZEPIN-3-YL)-2,3-BIS(3,3,3-TRIFLUOROPHENYL)BUTANEDIAMIDE(2R,3S)-N1-((3S)-5-(3-FLUOROPHENYL)-9-METHYL-2-OXO-2,3-DIHYDRO-1H-1,4-BENZODIAZEPIN-3-YL)-2,3-BIS(3,3,3-TRIFLUOROPHENYL)BUTANEDIAMIDEgamma-secretase inhibitor, antineoplastic, AL102, BMS 986115, LSK1L593UU, AL 102 BMS-986115 has been used in trials studying the treatment of Various Advanced Cancer. Varegacestat is an orally bioavailable, gamma secretase (GS) and pan-Notch inhibitor, with potential antineoplastic activity. Upon administration, varegacestat binds to GS and blocks the proteolytic cleavage …

Tigozertinib

Tigozertinib CAS 2660250-10-0 MF C28H37FN6O3S MW 556.7 3-Isoquinolinamine, N-[2-[(3S,4R)-3-fluoro-4-methoxy-1-piperidinyl]-4-pyrimidinyl]-5-(1-methylethyl)-8-[(2R,3S)-2-methyl-3- [(methylsulfonyl)methyl]-1-azetidinyl]- N-{2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl}-8-{(2R,3S)-3-[(methanesulfonyl)methyl]-2-methylazetidin-1-yl}-5-(propan-2-yl)isoquinolin-3-amine N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine N-(2-((3S,4R)-3-fluoro-4-methoxypiperidin-l-yl)pyrimidin-4-yl)-5-isopropyl-8-(3-(methylsulfonylmethyl)azetidin-l-yl)isoquinolin-3-amine epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, antineoplastic, PA4PTH5HL9, BLU 945 Tigozertinib (BLU-945) is currently under investigation in clinical trial NCT04862780 (Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC) for the treatment of NSCLC. Tigozertinib is a fourth-generation, orally bioavailable, …

Tambiciclib

Tambiciclib CAS 2247481-08-7 MF C25H35ClN6O2S, 519.10 4-[[[4-[5-chloro-2-[[4-[[(2R)-1-methoxypropan-2-yl]amino]cyclohexyl]amino]-4-pyridinyl]-1,3-thiazol-2-yl]amino]methyl]oxane-4-carbonitrile 2H-PYRAN-4-CARBONITRILE, 4-(((4-(5-CHLORO-2-((TRANS-4-(((1R)-2-METHOXY-1-METHYLETHYL)AMINO)CYCLOHEXYL)AMINO)-4-PYRIDINYL)-2-THIAZOLYL)AMINO)METHYL)TETRAHYDRO- cyclin-dependent kinase inhibitor, antineoplastic, GFH 009, JSH 009, XDZ7VK8CXC, Orphan Drug , Acute myeloid leukaemia, Peripheral T-cell lymphoma Tambiciclib (GFH009, JSH-009) is an orally active, highly potent and selective CDK9 inhibitor (IC50 = 1 nM), demonstrating >200-fold selectivity over other CDKs, >100-fold selectivity over DYRK1A/B, and excellent selectivity over 468 kinases/mutants. Tambiciclib …

Talorasib

Talorasib CAS 2648584-48-7 MFC32H34ClFN6O3 MW605.10 [(2S)-4-[(7S)-7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrileKirsten rat sarcoma viral oncogene homologue (KRAS)inhibitor, antineoplastic, 727W6T7DPK SYN CN115385923 https://patentscope.wipo.int/search/en/detail.jsf?docId=CN380619664&_cid=P20-MJ0TAW-52678-1 Preparation Example 1: Synthesis of the compound shown in formula (I) (1) Synthesis of Compound 1 Synthetic route of compound 1: Synthesis of compound 1-j 1-Bromo-8-chloronaphthalene (500 mg, 2.07 mmol) was dissolved in THF (20 mL), cooled to …

Talogreptide mesaroxetan

Talogreptide mesaroxetan CAS 1801418-23-4 MF C86H140N22O18 MW1770.17 {MeCOSar}-PEG4-{d-Phe}-Gln-Trp-Ala-Val-Gly-His-{Sta}-Leu-NH2 (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(3S,4S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-6-methyl-1-oxoheptan-4-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2R)-2-[3-[2-[2-[2-[2-[[5-[(8-methyl-3,6,10,13,16,19-hexazabicyclo[6.6.6]icosan-1-yl)amino]-5-oxopentanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-phenylpropanoyl]amino]pentanediamide N-{21-[(8-methyl-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosan-1-yl)amino] -17,21-dioxo-4,7,10,13-tetraoxa-16-azahenicosan-1-oyl}-D-phenylalanyl-L-glutaminyl-L-tryptophyl-L-alanyl-Lvalylglycyl-L-histidyl-(3S,4S)-4-amino-3-hydroxy-6-methylheptanoyl-L-leucinamidediagnostic imaging agent, antineoplastic, ZUN64K4H2X, SAR-BBN Talogreptide mesaroxetan (CAS 1801418-23-4) is a synthetic peptide, a complex molecule used as a diagnostic imaging agent with potential antitumor effects, targeting G-protein coupled receptors (GRPr) often overexpressed in cancers, allowing for specific tumor visualization in PET scans, particularly for …

Suvadronabinol

Suvadronabinol CAS 1225194-84-2 MF C30H43NO6 MW513.7 g/mol 4-{[(2S)-3-methyl-1-oxo-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl]oxy}butan-2-yl]amino}-4-oxobutanoic acid 3-{[(2S)-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6H,6aH,7H,8H,10aH-benzo[c]isochromen-1-yl]oxy}-3-methyl-1-oxobutan-2-yl]carbamoyl}propanoic acid 4-{[(2S)-3-methyl-1-oxo-1-{[(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b,d]pyran-1-yl]oxy}butan-2-yl]amino}-4-oxobutanoic acidcannabinoid receptor agonist, DB 21741, XV9S3R9XJC Suvadronabinol (DB21741) is a potent, synthetic small-molecule cannabinoid receptor type 1 (CB1) agonist, initially developed for therapeutic potential in areas like appetite stimulation, pain, or weight management, acting similarly to cannabis compounds but with specific design, currently in preclinical …

Surzetoclax

Surzetoclax CAS 2858632-01-4 MF C53H63ClN8O10S, 1039.64 NAMES 4-[(4aS,10aR)-14-(4-chlorophenyl)-12,12-dimethyl1,2,4a,5,8,9,10a,11,13,15-decahydro-7H,12Hpyrazino[2,1-g][1,5,8]benzodioxaazacycloundecin3(4H)-yl]-2-(3,4-dihydro-2Hpyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-[4-({[(2S,5R)-5-methoxyoxan-2-yl]methyl}amino)-3-nitrobenzene-1-sulfonyl]benzamide 4-(14-(4-chlorophenyl)-12,12-dimethyl-1,2,4a,5,8,9,10a,11,13,15-decahydro-7H,12H-benzo[f]pyrazino[2,1-c][1,8]dioxa[4]azacycloundecin-3(4H)-yl)-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)-N-((4-((((2S,5R)-5-methoxytetrahydro-2H-pyran-2-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamide D-erythro-Hexitol, 1,5-anhydro-6-[[4-[[[4-[(4aS,10aR)-14-(4-chlorophenyl)-1,2,4a,5,8,9,10a,11,13,15-decahydro-12,12-dimethyl-7H,12H-pyrazino[2,1-g][1,5,8]benzodioxaazacycloundecin-3(4H)-yl]-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzoyl]amino]sulfonyl]-2-nitrophenyl]amino]-3,4,6-trideoxy-2-O-methyl- 1,5-Anhydro-6-[[4-[[[4-[(4aS,10aR)-14-(4-chlorophenyl)-1,2,4a,5,8,9,10a,11,13,15-decahydro-12,12-dimethyl-7H,12H-pyrazino[2,1-g][1,5,8]benzodioxaazacycloundecin-3(4H)-yl]-2-(3,4-dihydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepin-1(7H)-yl)benzoyl]amino]sulfonyl]-2-nitrophenyl]amino]-3,4,6-trideoxy-2-O-methyl-D-erythro-hexitolB-cell lymphoma 2 (Bcl-2) inhibitor, antineoplastic, ABBV 453, C3TU3CHH6L, Bcl-2-IN-16 Surzetoclax, also known as ABBV 453; is a highly potent and selective BCL-2 inhibitor with a Ki of approximately 0.07 nM. It induces apoptosis in BCL-2–dependent hematologic cancer cells, showing EC50 values typically below …

Surlorian

Surlorian CAS 1467605-57-7 MFC18H19NO3S, 329.41 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acidryanodine receptor (RyR) stabilizer, ARM 210, RYCAL DMD, s48168, S 48168, 1033GN605L Surlorian (ARM210) is a novel drug candidate, specifically a Ryanodine Receptor (RyR) stabilizer developed by RyCarma Therapeutics, designed to treat heart failure by repairing leaky RyRs in heart and skeletal muscles, aiming to improve both cardiac function and muscle weakness …

Sumecigrel

Sumecigrel, VICAGREL CAS 1314081-53-2 MF C18H18ClNO4S MW379.858 methyl (S)-2-(acetyloxy)-6,7-dihydrothieno[3,2- c]pyridin-5(4H)-ylacetateplatelet aggregation inhibitor, 8A63K3TN0U, VICAGREL Sumecigrel (also known as vicagrel) is an investigational small molecule drug classified as a P2Y12 inhibitor and antiplatelet agent. It is currently under clinical development for the treatment of various cardiovascular and peripheral conditions. Key Information Chemical Details For more detailed …